TY - JOUR
T1 - Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease
AU - Ray Kim, W.
AU - Lindor, Keith D.
AU - Malinchoc, Michael
AU - Petz, Jan L.
AU - Jorgensen, Roberta
AU - Rolland Dickson, E.
N1 - Funding Information:
Abbreviations: QOL, quality of life; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SF-36, short form 36. From the 1Division of Gastroenterology and Hepatology, 2Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN. Received February 22, 2000; accepted August 7, 2000. Made possible by a grant (DK34238) from the National Institutes of Health. The instrument used in this study, the NIDDK-QA instrument, and scoring algorithm are available from the corresponding author. Address reprint requests to W. Ray Kim, M.D., Division of Gastroenterology and Hepatology (Ch10), Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905. E-mail: kim.woong@mayo.edu; fax: 507-266-2810. Copyright © 2000 by the American Association for the Study of Liver Diseases. 0270-9139/00/3205-0007$3.00/0 doi:10.1053/jhep.2000.19067
PY - 2000
Y1 - 2000
N2 - The NIDDK-QA instrument, developed and widely used in liver transplant recipients, assesses quality of life (QOL) in four domains, including liver disease symptoms, physical function, health satisfaction, and overall well-being. We investigated whether the instrument may be used as a disease-specific instrument in ambulatory patients with cholestatic liver disease. The NIDDK-QA instrument was administered in 96 patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) seen at the Mayo Clinic. The SF-36, a well-established generic instrument, was also administered. Standard measures for test-retest reliability, internal consistency, and discriminant and concurrent validity were examined. All patients were ambulatory with mostly normal levels of serum bilirubin and albumin concentrations. The reliability of the NIDDK-QA, as measured by test-retest correlation (Pearson coefficients: 0.82-0.99, P < .01) and by internal consistency (Cronbach's alpha: 0.87-0.94) exceeded conventional acceptability criteria. The correlation between domain scores of the NIDDK-QA and SF-36 was clear and logical in that the physical function domain of NIDDK-QA strongly correlated with the physical component summary score of SF-36 (r = 0.86, P < .01). The overall well-being domain of the NIDDK-QA was closely associated with the mental summary score of SF-36 (r = 0.69, P < .01). Among PBC patients, there was a modest yet significant correlation between the Mayo risk score and overall well-being (r = -0.26, P = .03). In the assessment of QOL in patients with cholestatic liver disease, NIDDK-QA is found reliable and valid. These data, combined with our previous study, demonstrate its applicability in a wide spectrum of disease severity, ranging from early, ambulatory-phase disease to decompensated cirrhosis necessitating liver transplantation.
AB - The NIDDK-QA instrument, developed and widely used in liver transplant recipients, assesses quality of life (QOL) in four domains, including liver disease symptoms, physical function, health satisfaction, and overall well-being. We investigated whether the instrument may be used as a disease-specific instrument in ambulatory patients with cholestatic liver disease. The NIDDK-QA instrument was administered in 96 patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) seen at the Mayo Clinic. The SF-36, a well-established generic instrument, was also administered. Standard measures for test-retest reliability, internal consistency, and discriminant and concurrent validity were examined. All patients were ambulatory with mostly normal levels of serum bilirubin and albumin concentrations. The reliability of the NIDDK-QA, as measured by test-retest correlation (Pearson coefficients: 0.82-0.99, P < .01) and by internal consistency (Cronbach's alpha: 0.87-0.94) exceeded conventional acceptability criteria. The correlation between domain scores of the NIDDK-QA and SF-36 was clear and logical in that the physical function domain of NIDDK-QA strongly correlated with the physical component summary score of SF-36 (r = 0.86, P < .01). The overall well-being domain of the NIDDK-QA was closely associated with the mental summary score of SF-36 (r = 0.69, P < .01). Among PBC patients, there was a modest yet significant correlation between the Mayo risk score and overall well-being (r = -0.26, P = .03). In the assessment of QOL in patients with cholestatic liver disease, NIDDK-QA is found reliable and valid. These data, combined with our previous study, demonstrate its applicability in a wide spectrum of disease severity, ranging from early, ambulatory-phase disease to decompensated cirrhosis necessitating liver transplantation.
UR - http://www.scopus.com/inward/record.url?scp=0033765330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033765330&partnerID=8YFLogxK
U2 - 10.1053/jhep.2000.19067
DO - 10.1053/jhep.2000.19067
M3 - Article
C2 - 11050040
AN - SCOPUS:0033765330
SN - 0270-9139
VL - 32
SP - 924
EP - 929
JO - Hepatology
JF - Hepatology
IS - 5
ER -